Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group A: Saline Group Clear all
Terminated Not applicable Interventional

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

NCT01996111
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
Procedure
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

NCT00825916
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

NCT00189540
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions
HGF plasmid, Placebo
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

NCT01610414
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
23
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

NCT02876055
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

NCT03415243
View directory record Official record
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)

NCT03711474
View directory record Official record
Conditions
Dysphagia
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 18, 2026, 8:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision

NCT00839787
View directory record Official record
Conditions
Abdominal Pain
Interventions
Morphine Sulfate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 8:57 AM EDT
Not yet recruiting Not applicable Interventional

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

NCT06953635
View directory record Official record
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

NCT02337855
View directory record Official record
Conditions
Schistosomiasis
Interventions
Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Phentermine and B12 on Weight Loss Among Obese Patients

NCT01719185
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Phentermine and B12, Phentermine
Drug
Lead sponsor
Dr. Michael Lang
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 8:57 AM EDT
Terminated Not applicable Interventional Results available

Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study

NCT01411917
View directory record Official record
Conditions
Ileostomy - Stoma
Interventions
Transversus abdominis plane block
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 18, 2026, 8:57 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 8:57 AM EDT
Not yet recruiting Phase 3 Interventional

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

NCT07632157
View directory record Official record
Conditions
Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2g, Magnesium Sulfate 4g, Saline (0.9% NaCl)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
View directory record Official record
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

NCT02427529
View directory record Official record
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

NCT02221219
View directory record Official record
Conditions
Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Renal Injury
Interventions
Indomethacin, delay in umbilical cord clamp at birth, placebo infusion, immediate cord clamp at birth
Drug · Procedure
Lead sponsor
Hong Huang
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669
View directory record Official record
Conditions
Virus Diseases
Interventions
Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Saline Placebo, RabAvert
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01006369
View directory record Official record
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 18, 2026, 8:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

NCT00379236
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
EUFLEXXA™, placebo
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 18, 2026, 8:57 AM EDT